Anthony Digiandomenico - May 2, 2023 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)

Role
Director
Signature
/s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact
Stock symbol
NDRA
Transactions as of
May 2, 2023
Transactions value $
$100,416
Form type
4
Date filed
5/3/2023, 04:07 PM
Previous filing
Feb 1, 2023
Next filing
Aug 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NDRA Common Stock Purchase $100K +83.3K +436.28% $1.20 102K May 2, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NDRA Warrants Purchase $417 +41.7K $0.01* 41.7K May 2, 2023 Common Stock 41.7K $1.40 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares purchased in the Registrant's underwritten public offering that closed May 2, 2023 (the "Offering").
F2 The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant in the Offering.
F3 Represents warrants purchased in the Offering. The warrants were offered and sold at the rate of one warrant to purchase one share for every two shares of common stock purchased in the Offering.